Background: Vertebral fractures (VFs) are a frequent complication of acromegaly, but no studies have been so far published on effectiveness of anti-osteoporotic drugs in this clinical setting. Objective: To evaluate whether in real-life clinical practice bone-active drugs may reduce the risk of VFs in patients with active or controlled acromegaly. Study design: Retrospective-longitudinal study including 9 tertiary care Endocrine Units. Patients and methods: Two-hundred-forty-eight patients with acromegaly (104 males; mean age 56.0±13.6 years) were evaluated for prevalent and incident VFs by quantitative morphometric approach. Bone-active agents were used in 52 patients (20.97%) and the median period of follow-up was 48 months (range 12-132). Results: During the follow-up, 65 patients (26.21%) developed incident VFs in relationship with pre-existing VFs (odds ratio (OR) 3.75; p<0.001), duration of active acromegaly (OR 1.01; p=0.04), active acromegaly at the study entry (OR 2.48; p=0.007) and treated hypoadrenalism (OR 2.50; p=0.005). In the entire population, treatment with bone active drugs did not have a significant effect on incident VFs (p=0.82). However, in a sensitive analysis restricted to patients with active acromegaly at the study entry (111 cases), treatment with bone-active drugs was associated with a lower risk of incident VFs (OR 0.11; p=0.004), independently of prevalent VFs (OR 7.65; p<0.001) and treated hypoadrenalism (OR 3.86; p=0.007). Conclusions: Bone-active drugs may prevent VFs in patients with active acromegaly.
Treatment of Acromegalic Osteopathy in Real-Life Clinical Practice: The BAAC (Bone Active drugs in ACromegaly) Study / G. Mazziotti, C. Battista, F. Maffezzoni, S. Chiloiro, E. Ferrante, N. Prencipe, L. Grasso, F. Gatto, R. Olivetti, M. Arosio, M. Barale, A. Bianchi, M. Cellini, I. Chiodini, L. De Marinis, G. Del Sindaco, C. Di Somma, A. Ferlin, E. Ghigo, A. Giampietro, S. Grottoli, E. Lavezzi, G. Mantovani, E. Morenghi, R. Pivonello, T. Porcelli, M. Procopio, F. Pugliese, A. Scillitani, A.G. Lania. - In: THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. - ISSN 0021-972X. - (2020). [Epub ahead of print] [10.1210/clinem/dgaa363]
Treatment of Acromegalic Osteopathy in Real-Life Clinical Practice: The BAAC (Bone Active drugs in ACromegaly) Study
E. Ferrante;M. Arosio;I. Chiodini;G. Del Sindaco;E. Lavezzi;G. Mantovani;E. Morenghi;A.G. Lania
Ultimo
2020
Abstract
Background: Vertebral fractures (VFs) are a frequent complication of acromegaly, but no studies have been so far published on effectiveness of anti-osteoporotic drugs in this clinical setting. Objective: To evaluate whether in real-life clinical practice bone-active drugs may reduce the risk of VFs in patients with active or controlled acromegaly. Study design: Retrospective-longitudinal study including 9 tertiary care Endocrine Units. Patients and methods: Two-hundred-forty-eight patients with acromegaly (104 males; mean age 56.0±13.6 years) were evaluated for prevalent and incident VFs by quantitative morphometric approach. Bone-active agents were used in 52 patients (20.97%) and the median period of follow-up was 48 months (range 12-132). Results: During the follow-up, 65 patients (26.21%) developed incident VFs in relationship with pre-existing VFs (odds ratio (OR) 3.75; p<0.001), duration of active acromegaly (OR 1.01; p=0.04), active acromegaly at the study entry (OR 2.48; p=0.007) and treated hypoadrenalism (OR 2.50; p=0.005). In the entire population, treatment with bone active drugs did not have a significant effect on incident VFs (p=0.82). However, in a sensitive analysis restricted to patients with active acromegaly at the study entry (111 cases), treatment with bone-active drugs was associated with a lower risk of incident VFs (OR 0.11; p=0.004), independently of prevalent VFs (OR 7.65; p<0.001) and treated hypoadrenalism (OR 3.86; p=0.007). Conclusions: Bone-active drugs may prevent VFs in patients with active acromegaly.File | Dimensione | Formato | |
---|---|---|---|
134 -Treatment of acromegalic osteopathy in real life - JCEM 2020 epub.pdf
Open Access dal 09/06/2021
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
574.11 kB
Formato
Adobe PDF
|
574.11 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.